Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Ignores Tobacco Harm Reduction As Therapeutic Option – Experts

This article was originally published in The Tan Sheet

Executive Summary

FDA's tobacco product policies impede development of alternatives to smoking-cessation products with utility for harm reduction, according to an expert panel.
Advertisement

Related Content

New Products In Brief
New Products In Brief
New Products In Brief
Advisory Committee On NRT Indications Appears Likely Following Workshop
FDA Will Mull OTC Smoking Cessation Long-Term Use As Support Builds
FDA's Tobacco Center To Mull First Modified-Risk Claim Application
FDA's Tobacco Center To Mull First Modified-Risk Claim Application

Topics

Advertisement
UsernamePublicRestriction

Register

PS104988

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel